Loading
German ADC company whose NaPi2b ADC TUB-040 posted a 59% response rate in platinum-resistant ovarian cancer; Gilead bought it in May 2026 for $3.15B upfront and up to $1.85B in milestones.
Raised a record €344M Series C (October 2025) after TUB-040 phase 1/2a data at ESMO 2025 (59% ORR in platinum-resistant ovarian cancer; also lung adenocarcinoma). Gilead completed its acquisition on 21 May 2026, paying $3.15B upfront with up to $1.85B in contingent milestones; the acquisition also brought TUB-030, a 5T4-targeted ADC, and the team stays in Munich. Proprietary Tubutecan and P5 conjugation chemistries.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Upfront consideration on a cash-free, debt-free basis, plus up to 1.85 billion US dollars in contingent milestones; completed 21 May 2026 | 2026 | $3.1B | gilead.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Gilead Sciences (incl. Kite), Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/